183 related articles for article (PubMed ID: 19818735)
1. Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing.
Zhao Y; Zhang CL; Zeng BF; Wu XS; Gao TT; Oda Y
Biochem Biophys Res Commun; 2009 Dec; 390(3):642-7. PubMed ID: 19818735
[TBL] [Abstract][Full Text] [Related]
2. Enhanced chemosensitivity by simultaneously inhibiting cell cycle progression and promoting apoptosis of drug-resistant osteosarcoma MG63/DXR cells by targeting Cyclin D1 and Bcl-2.
Zhang C; Zhao Y; Zeng B
Cancer Biomark; 2012; 12(4):155-67. PubMed ID: 23568006
[TBL] [Abstract][Full Text] [Related]
3. Novel gene P28GANK confers multidrug resistance by modulating the expression of MDR-1, Bcl-2 and Bax in osteosarcoma cells.
Wang G; Rong J; Zhou Z; Duo J
Mol Biol (Mosk); 2010; 44(6):1010-7. PubMed ID: 21287809
[TBL] [Abstract][Full Text] [Related]
4. Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway.
Spina A; Sorvillo L; Di Maiolo F; Esposito A; D'Auria R; Di Gesto D; Chiosi E; Naviglio S
J Cell Physiol; 2013 Jan; 228(1):198-206. PubMed ID: 22674530
[TBL] [Abstract][Full Text] [Related]
5. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells.
Lima RT; Martins LM; Guimarães JE; Sambade C; Vasconcelos MH
Cancer Gene Ther; 2004 May; 11(5):309-16. PubMed ID: 15031723
[TBL] [Abstract][Full Text] [Related]
6. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y
Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin in a human osteosarcoma cell line.
Liu SY; Song SX; Lin L; Liu X
Chemotherapy; 2010; 56(2):101-7. PubMed ID: 20357441
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis.
Yuan XW; Zhu XF; Huang XF; Sheng PY; He AS; Yang ZB; Deng R; Feng GK; Liao WM
Acta Pharmacol Sin; 2007 Nov; 28(11):1835-41. PubMed ID: 17959036
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia.
Ji M; Li J; Yu H; Ma D; Ye J; Sun X; Ji C
Br J Haematol; 2009 Jun; 145(5):648-56. PubMed ID: 19344413
[TBL] [Abstract][Full Text] [Related]
10. Telomerase activity, expression of Bcl-2 and cell cycle regulation in doxorubicin resistant gastric carcinoma cell lines.
Yoon KA; Ku JL; Yang JO; Park JG
Int J Mol Med; 2003 Mar; 11(3):343-8. PubMed ID: 12579337
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2 gene silencing in pediatric epithelial liver tumors.
Warmann SW; Frank H; Heitmann H; Ruck P; Herberts T; Seitz G; Fuchs J
J Surg Res; 2008 Jan; 144(1):43-8. PubMed ID: 17574594
[TBL] [Abstract][Full Text] [Related]
12. Sensitizing osteosarcoma stem cells to doxorubicin-induced apoptosis through retention of doxorubicin and modulation of apoptotic-related proteins.
Gonçalves C; Martins-Neves SR; Paiva-Oliveira D; Oliveira VE; Fontes-Ribeiro C; Gomes CM
Life Sci; 2015 Jun; 130():47-56. PubMed ID: 25818183
[TBL] [Abstract][Full Text] [Related]
13. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.
Pasello M; Hattinger CM; Stoico G; Manara MC; Benini S; Geroni C; Mercuri M; Scotlandi K; Picci P; Serra M
Eur J Cancer; 2005 Sep; 41(14):2184-95. PubMed ID: 16140527
[TBL] [Abstract][Full Text] [Related]
14. Bufalin induces apoptosis in human osteosarcoma U-2OS and U-2OS methotrexate300-resistant cell lines.
Yin JQ; Shen JN; Su WW; Wang J; Huang G; Jin S; Guo QC; Zou CY; Li HM; Li FB
Acta Pharmacol Sin; 2007 May; 28(5):712-20. PubMed ID: 17439728
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
Gazitt Y; Kolaparthi V; Moncada K; Thomas C; Freeman J
Int J Oncol; 2009 Feb; 34(2):551-61. PubMed ID: 19148492
[TBL] [Abstract][Full Text] [Related]
16. [Establishment of a cisplatin-multidrug resistance cell line of human osteosarcoma].
Zhang WT; Tu CQ; Liu Y; Li SF
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):262-5. PubMed ID: 16608090
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin enhances the chemosensitivity of GBC-SD cell line to doxorubicin through arresting the cell cycle to S phase rather than through the P53/Bax-depended apoptosis way in vitro.
Songgang L; Jiyu L; Gongwei ; Yingbin L; Yiyu Q; Zhiwei Q
Hepatogastroenterology; 2009; 56(94-95):1253-60. PubMed ID: 19950772
[TBL] [Abstract][Full Text] [Related]
18. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines.
Luk F; Yu Y; Walsh WR; Yang JL
Cancer Invest; 2011 Oct; 29(8):521-32. PubMed ID: 21843050
[TBL] [Abstract][Full Text] [Related]
19. Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells.
Feng T; Qiao G; Feng L; Qi W; Huang Y; Yao Y; Shen Z
Mol Med Rep; 2014 Dec; 10(6):2985-92. PubMed ID: 25310700
[TBL] [Abstract][Full Text] [Related]
20. Resistance to cisplatin and adriamycin is associated with the inhibition of glutathione efflux in MCF-7-derived cells.
Osbild S; Brault L; Battaglia E; Bagrel D
Anticancer Res; 2006; 26(5A):3595-600. PubMed ID: 17094488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
